Study Shows Link Between Low Sperm Count, Birth Defects Should Not be of Concern - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Study Shows Link Between Low Sperm Count, Birth Defects Should Not be of Concern Assessment of sperm quality suggests no association with congenital anomalies


Study Shows Link Between Low Sperm Count, Birth Defects Should Not be of Concern

Assessment of sperm quality suggests no association with congenital anomalies

PR Newswire

ORLANDO, Fla., May 18, 2014 /PRNewswire-USNewswire/ -- Birth defects do not appear to be associated with the father's semen quality, according to a new study at the 109th Annual Scientific Meeting of the American Urological Association (AUA). The study, conducted by researchers from Baylor College of Medicine, Stanford University and the Texas Department of State Health Services, will be presented to reporters during a special press conference at the Orange County Convention Center, Orlando, FL on Sunday, May 18 at 9:45 a.m. ET.

Approximately 15 percent of couples have difficulty conceiving, and in nearly 40 percent of these couples, the male partner is either the sole cause or a contributing cause to infertility. The treatment of male infertility depends upon the underlying cause, which may include no or low sperm count or poor sperm motility (movement). Assisted reproductive technologies (ART), such as in vitro fertilization (IVF), can often help. While ART have greatly enhanced the ability of couples to conceive, previous studies suggest an increased risk for congenital defects exists in children conceived using this technology as a result of male infertility factors. Researchers sought to determine if the severity of male infertility, as assessed by sperm quality, had an impact on the rate of birth defects when ART is used.  

Study Details 
Researchers used hierarchical linear modeling to determine odds ratios between birth defects and semen parameters on data collected from the Baylor College of Medicine Semen Database (BCMSD). Before linear modeling occurred, semen analysis data in the BCMSD was linked with offspring data from the Texas Birth Defects Registry (TBDRF) between 1999 and 2009.

Results showed:

  • Of the 6,087 men with linked data between BCMSD and TBDRF  -  1,382 had been evaluated for infertility.
  • Review of these data indicated 109 infants with and 2,115 infants without birth defects. There was no statistically significant association between semen quality and birth defect rates. 

"For couples considering assisted reproductive technology, the results of this study show they should not be concerned about decreased semen quality and birth defects," said Tobias S. Köhler, MD, MPH, FACS; session moderator and associate professor & residency program director with Southern Illinois University School of Medicine.  "More than five million happy and healthy babies have been conceived using these techniques."

About the American Urological Association : The 109th Annual Meeting of the American Urological Association takes place May 16 – 21 at the Orange County Convention Center in Orlando, FL.

Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 20,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.

Contact:
Christine Frey, AUA
410-999-7091, cfrey@AUAnet.org

SOURCE American Urological Association

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here